TrialThe British journal of dermatology2025

Efficacy and safety of rigosertib in patients with recessive dystrophic epidermolysis bullosa-associated advanced/metastatic cutaneous squamous cell carcinoma.

Martin Laimer et al.PubMed ↗Publisher ↗

No numbers read from the abstract.